Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Tabla 3.
Tratamientos más frecuentes
| Fármaco | Porcentaje (%) |
|---|---|
| Hidroxicloroquina | 85 |
| Lopinavir-ritonavir | 40 |
| Corticoides | 27 |
| Interferón | 6 |
| Tocilizumab | 5 |